Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

By D. Praticò, Christopher M. Clark, Feyan Liun, J. Rokach, V. Lee, John Q. Trojanowski. Archives of Neurology, 2002

614 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/9849c22506b9583f4d4380a0cc018e36acf5e80d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. I. Dalle-Donne
2. Barry Halliwell
3. M. Whiteman
4. R. Rossi
5. R. Colombo
6. D. Giustarini
7. A. Milzani
8. P. Barnes

Citations in the corpus

• Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI) (2005, unknown): “[3] Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ.”
• Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. (2004, background): “[190] Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ.”
• Biomarkers of oxidative damage in human disease. (2006, background): “Concentrations of F2- and F4-isoprostanes [which arise from oxidation of docosahexaenoic acid, an abundant unsaturated fatty acid in the central nervous system (CNS) and are often called neuroprostanes], are increased in the cerebrospinal fluid from AD patients (2, 43, 50– 52, 83, 84) and may even b”
• Isoprostanes: markers and mediators of oxidative stress (2004, background): “Alzheimer’s disease (48, 49) suggests a causative role”
• Expression of Nrf2 in Neurodegenerative Diseases (2007, unknown): “Oxidative damage occurs early in disease (5, 7), suggesting that oxidative stress plays a role in disease progression.”
• Oxidative Stress and Mitochondrial Dysfunction in Alzheimer’s Disease (2013, unknown): “For example, the levels of the isoprostane 8,12-iso -iPF 2 α -VI were signi fi - cantly increased in cerebrospinal fl uid, plasma, and urine of MCI subjects compared with age-matched control subjects, whereas the levels of AD cerebrospinal fl uid markers such as A β or tau remained unchanged [54].”
• Pharmacological and Clinical Aspects of Heme Oxygenase (2008, unknown): “Also increased oxidative damage (Nunomura et al., 2001; Praticò et al., 2002), iron accumulation (Schipper, 2004a). and HO-1 induction (Schipper et al., 1995) have been reported.”
• Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? (2004, background): “…are elevated in CSF from AD patients (Montine et al., 1998; 2002; Pratico et al., 2000), and may even be elevated prior to the development of AD (Pratico et al., 2001; 2002), consistent with the view that peroxidation may be an important step in progressive neuronal injury leading to clinically…”
• Mild cognitive impairment (2006, background): “Preliminary data indicate that an elevated level of F2-isoprostane 8,12-iso-iPF2α-VI in cerebrospinal fluid, plasma, or urine and the level of sulfatide in cerebrospinal fluid may be predictors of dementia as well (Pratico et al., 2002; Han et al., 2003).”